XWELL Inc.
XWELL, Inc. provides health and wellness services to travelers in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests to airport empl… Read more
XWELL Inc. (XWEL) - Net Assets
Latest net assets as of September 2025: $3.07 Million USD
Based on the latest financial reports, XWELL Inc. (XWEL) has net assets worth $3.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.74 Million) and total liabilities ($18.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.07 Million |
| % of Total Assets | 14.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.37% |
| 10-Year Change | -80.89% |
| Growth Volatility | 50.47 |
XWELL Inc. - Net Assets Trend (2008–2024)
This chart illustrates how XWELL Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XWELL Inc. (2008–2024)
The table below shows the annual net assets of XWELL Inc. from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.74 Million | -63.08% |
| 2023-12-31 | $20.97 Million | -56.26% |
| 2022-12-31 | $47.95 Million | -52.02% |
| 2021-12-31 | $99.94 Million | +24.34% |
| 2020-12-31 | $80.37 Million | +3269.20% |
| 2019-12-31 | $-2.54 Million | -119.31% |
| 2018-12-31 | $13.13 Million | -71.35% |
| 2017-12-31 | $45.84 Million | -28.57% |
| 2016-12-31 | $64.17 Million | +58.38% |
| 2015-12-31 | $40.52 Million | +29.94% |
| 2014-12-31 | $31.18 Million | -72.72% |
| 2013-12-31 | $114.28 Million | -22.96% |
| 2012-12-31 | $148.33 Million | +12832.36% |
| 2011-12-31 | $-1.17 Million | -387.45% |
| 2010-12-31 | $-239.00K | +98.54% |
| 2009-12-31 | $-16.38 Million | -49.30% |
| 2008-12-31 | $-10.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XWELL Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45873000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.00K | % |
| Other Comprehensive Income | $-1.96 Million | % |
| Other Components | $473.82 Million | % |
| Total Equity | $-788.00K | 100.00% |
XWELL Inc. Competitors by Market Cap
The table below lists competitors of XWELL Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Carmell Therapeutics Corporation
NASDAQ:CTCX
|
$2.26 Million |
|
Noronex Ltd
AU:NRX
|
$2.26 Million |
|
Anik Industries Limited
NSE:ANIKINDS
|
$2.26 Million |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
$2.26 Million |
|
Wahana Pronatural
JK:WAPO
|
$2.25 Million |
|
Gasporox AB (publ)
ST:GPX
|
$2.25 Million |
|
Ronin Resources Ltd
AU:RON
|
$2.25 Million |
|
Avalon GloboCare Corp.
NASDAQ:ALBT
|
$2.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XWELL Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,002,000 to -788,000, a change of -13,790,000 (-106.1%).
- Net loss of 16,853,000 reduced equity.
- New share issuances of 1,355,000 increased equity.
- Other comprehensive income decreased equity by 35,000.
- Other factors increased equity by 1,743,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.85 Million | -2138.71% |
| Share Issuances | $1.35 Million | +171.95% |
| Other Comprehensive Income | $-35.00K | -4.44% |
| Other Changes | $1.74 Million | +221.19% |
| Total Change | $- | -106.06% |
Book Value vs Market Value Analysis
This analysis compares XWELL Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-10497.61 | $1.41 | x |
| 2009-12-31 | $-6.85 | $1.41 | x |
| 2010-12-31 | $-531.11 | $1.41 | x |
| 2011-12-31 | $-1405.31 | $1.41 | x |
| 2012-12-31 | $42722.35 | $1.41 | x |
| 2013-12-31 | $16467.15 | $1.41 | x |
| 2014-12-31 | $4135.28 | $1.41 | x |
| 2015-12-31 | $4758.75 | $1.41 | x |
| 2016-12-31 | $4709.87 | $1.41 | x |
| 2017-12-31 | $2201.32 | $1.41 | x |
| 2018-12-31 | $375.86 | $1.41 | x |
| 2019-12-31 | $-76.34 | $1.41 | x |
| 2020-12-31 | $34.92 | $1.41 | x |
| 2021-12-31 | $17.65 | $1.41 | x |
| 2022-12-31 | $8.53 | $1.41 | x |
| 2023-12-31 | $3.11 | $1.41 | x |
| 2024-12-31 | $-0.17 | $1.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XWELL Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.72%
- • Asset Turnover: 1.34x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-80.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.24 Million |
| 2009 | 0.00% | -30745.00% | 0.01x | 0.00x | $-4.51 Million |
| 2010 | 0.00% | -4711.85% | 0.04x | 0.00x | $-9.92 Million |
| 2011 | 0.00% | -1041.64% | 0.38x | 0.00x | $-7.36 Million |
| 2012 | -14.05% | -5647.97% | 0.00x | 1.06x | $-35.67 Million |
| 2013 | -45.88% | -4766.64% | 0.01x | 1.08x | $-63.86 Million |
| 2014 | -351.75% | -7696.63% | 0.04x | 1.20x | $-112.80 Million |
| 2015 | -27.54% | -49.18% | 0.45x | 1.25x | $-15.21 Million |
| 2016 | -40.33% | -126.52% | 0.23x | 1.39x | $-29.96 Million |
| 2017 | -70.54% | -59.07% | 0.75x | 1.60x | $-32.93 Million |
| 2018 | -408.58% | -74.27% | 1.64x | 3.36x | $-38.12 Million |
| 2019 | 0.00% | -43.75% | 1.69x | 0.00x | $-20.60 Million |
| 2020 | -116.30% | -1079.17% | 0.08x | 1.33x | $-98.27 Million |
| 2021 | 3.61% | 4.54% | 0.58x | 1.37x | $-5.92 Million |
| 2022 | -82.24% | -58.70% | 0.79x | 1.76x | $-36.83 Million |
| 2023 | -213.36% | -92.14% | 0.77x | 3.00x | $-29.04 Million |
| 2024 | 0.00% | -49.72% | 1.34x | 0.00x | $-16.77 Million |
Industry Comparison
This section compares XWELL Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XWELL Inc. (XWEL) | $3.07 Million | 0.00% | 6.09x | $2.25 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |